| abstract |
The present invention relates to new compounds, in particular new pyridinone derivatives of the formula (I), where all the radicals are as defined in the description and claims. The compounds of the invention are positive allosteric modulators of subtype 2 metabotropic receptors (“mGluR2”), useful for treating or preventing neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 metabotropic receptor subtype is involved. In particular, such diseases are disorders of the central nervous system selected from the group of anxiety, schizophrenia, migraine, depression and epilepsy. The invention also relates to pharmaceutical compositions and methods for preparing such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved. |